false
OasisLMS
Catalog
2025 Multiprofessional Critical Care Review: Adult ...
10: Venous Thromboembolism
10: Venous Thromboembolism
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Steve Pastoris from Memorial Sloan Kettering Cancer Center discusses venous thromboembolism (VTE), covering venous thrombosis, pulmonary embolism (PE), and their treatments. VTE, being the third most frequent cardiovascular syndrome, affects 370,000 in the U.S. annually, leading to 60,000-100,000 deaths and incurring $7-$10 billion in healthcare costs. Risk factors include cancer, surgery, trauma, immobilization, and others like pregnancy and genetic mutations. Diagnostic techniques like venous duplex ultrasound and blood analysis (D-dimer) are emphasized. PE classifications range from low to high risk, with distinct treatments like anticoagulation, thrombolysis, and catheter-directed therapies. High-risk PE often requires reperfusion therapy while intermediate-risk PE patients are closely monitored. While thrombolytics may rapidly stabilize PE, they entail bleeding risks; catheter-directed approaches offer alternative treatments. Prospective anticoagulation duration for PE is three months with extensions based on risk. IVC filters are reserved for cases where anticoagulation is contraindicated. Thromboprophylaxis is critical in ICU settings, as corroborated by trials like PREVENT. Pulmonary embolism response teams (PERT) enhance treatment outcomes by tailoring expert interventions.
Keywords
venous thromboembolism
pulmonary embolism
anticoagulation
thrombolysis
diagnostic techniques
risk factors
thromboprophylaxis
×
Please select your language
1
English